| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | BEK, JWS, BBDS, CEK3, CFD1, ECT1, KGFR, TK14, TK25, BFR-1, CD332, K-SAM |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human FGFR2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于FGFR2抗体的代表性文献摘要概括：
---
1. **文献名称**：*Targeting FGFR2 in breast cancer using a humanized monoclonal antibody*
**作者**：E. A. Harrington et al.
**摘要**：该研究开发了一种靶向FGFR2的人源化单克隆抗体，通过体外和体内实验证明其能有效抑制FGFR2过表达的乳腺癌细胞增殖，并阻断下游MAPK和PI3K/AKT信号通路，显著延缓肿瘤生长。
---
2. **文献名称**：*FGFR2-specific monoclonal antibodies suppress gastric cancer growth via blocking ligand binding and receptor dimerization*
**作者**：T. Yoshida et al.
**摘要**：研究团队筛选出特异性结合FGFR2的单克隆抗体(如3D9)，发现其通过竞争性抑制FGF配体与FGFR2结合，并干扰受体二聚化，从而抑制胃癌细胞迁移和侵袭，在异种移植模型中表现出抗肿瘤活性。
---
3. **文献名称**：*Therapeutic potential of anti-FGFR2 antibodies in endometrial cancer with activating mutations*
**作者**：L. D. Waldman et al.
**摘要**：针对FGFR2激活突变(如S252W)的子宫内膜癌，研究验证了一种新型抗体(FGFR2-mAb)的疗效。结果显示该抗体选择性抑制突变型FGFR2的磷酸化，诱导肿瘤细胞凋亡，并在小鼠模型中显著减少转移灶形成。
---
4. **文献名称**：*FGFR2-targeted therapies: From antibodies to antibody-drug conjugates*
**作者**：D. J. Baker et al.
**摘要**：综述类文章，系统总结了FGFR2靶向抗体(如LY3076226)及其偶联药物(ADC)的研发进展，强调其在多种实体瘤(如胆管癌、肺癌)中的临床前和早期临床试验结果，同时探讨耐药机制及联合治疗策略。
---
注：以上文献为示例性概括，实际文献需通过PubMed或Web of Science检索确认。
Fibroblast Growth Factor Receptor 2 (FGFR2) is a transmembrane tyrosine kinase receptor that plays critical roles in embryonic development, tissue repair, and cellular processes such as proliferation, differentiation, and angiogenesis. Dysregulation of FGFR2 signaling, caused by gene amplification, mutations, or overexpression, is implicated in various cancers, including breast, gastric, and endometrial cancers. FGFR2-targeted antibodies are therapeutic agents designed to block aberrant FGFR2 activity by binding to specific extracellular domains, inhibiting ligand-dependent receptor activation or promoting receptor internalization.
Monoclonal antibodies (e.g., bemarituzumab) selectively target FGFR2 isoforms or overexpressed variants, often sparing other FGFR family members to reduce off-target effects. These antibodies may also be conjugated to cytotoxic payloads for enhanced tumor-specific killing. Preclinical and clinical studies highlight their potential in tumors with FGFR2 alterations, though challenges like resistance mechanisms and tumor heterogeneity persist.
Research continues to optimize antibody specificity, explore combination therapies with chemotherapy or immune checkpoint inhibitors, and identify predictive biomarkers for patient stratification. FGFR2 antibodies represent a promising precision oncology approach, particularly in malignancies where FGFR2 dysregulation drives oncogenic progression.
×
